BRPI0817516A2 - Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino - Google Patents

Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino

Info

Publication number
BRPI0817516A2
BRPI0817516A2 BRPI0817516-0A BRPI0817516A BRPI0817516A2 BR PI0817516 A2 BRPI0817516 A2 BR PI0817516A2 BR PI0817516 A BRPI0817516 A BR PI0817516A BR PI0817516 A2 BRPI0817516 A2 BR PI0817516A2
Authority
BR
Brazil
Prior art keywords
amyloid
microgliosis
neurotoxicity
reducing
deposition
Prior art date
Application number
BRPI0817516-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael J Mullan
Daniel Paris
Robert A Ivey Iii
Original Assignee
Alzheimer S Inst Of America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheimer S Inst Of America Inc filed Critical Alzheimer S Inst Of America Inc
Publication of BRPI0817516A2 publication Critical patent/BRPI0817516A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0817516-0A 2007-10-05 2008-10-03 Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino BRPI0817516A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97795307P 2007-10-05 2007-10-05
US4610908P 2008-04-18 2008-04-18
PCT/US2008/078786 WO2009046323A1 (en) 2007-10-05 2008-10-03 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Publications (1)

Publication Number Publication Date
BRPI0817516A2 true BRPI0817516A2 (pt) 2015-06-16

Family

ID=40523447

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817516-0A BRPI0817516A2 (pt) 2007-10-05 2008-10-03 Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino

Country Status (16)

Country Link
US (2) US8236346B2 (enExample)
EP (1) EP2214666B1 (enExample)
JP (1) JP5411145B2 (enExample)
KR (1) KR101417200B1 (enExample)
CN (1) CN101883564B (enExample)
AU (1) AU2008308519B2 (enExample)
BR (1) BRPI0817516A2 (enExample)
CA (1) CA2701620C (enExample)
DK (1) DK2214666T3 (enExample)
ES (1) ES2449594T3 (enExample)
MX (1) MX2010003669A (enExample)
NZ (1) NZ584729A (enExample)
PL (1) PL2214666T3 (enExample)
RU (1) RU2490014C2 (enExample)
TW (1) TWI500422B (enExample)
WO (1) WO2009046323A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
CN112826794B (zh) 2019-11-06 2022-02-11 上海交通大学医学院 一种靶向修复神经血管病变的纳米复合物及其制备与应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS61129140A (ja) 1984-11-27 1986-06-17 Nitto Electric Ind Co Ltd 医薬組成物
GB8431119D0 (en) * 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
DE3877630T2 (de) 1987-06-12 1993-06-03 American Cyanamid Co Transkutane verabreichung von pharmazeutika.
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US5508413A (en) * 1987-08-27 1996-04-16 Fujisawa Pharmaceutical Co., Ltd. (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
EP0317780B1 (en) 1987-11-25 1992-05-20 American Cyanamid Company Sustained (controlled) release delivery system for substituted dihydropyridine calcium channel blockers
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2718105B2 (ja) 1988-10-27 1998-02-25 藤沢薬品工業株式会社 （＋）−２−シアノ−６−メチル−４−（３−ニトロフェニル）−１，４−ジヒドロピリジン−３，５−ジカルボン酸５−イソプロピル３−メチルの光安定性結晶
JP3479532B2 (ja) * 1989-03-31 2003-12-15 ザ・チルドレンズ・メディカル・センター・コーポレーション エイズの痴呆症、脊髄障害および失明の治療
JPH0381262A (ja) 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン系カルシウム拮抗薬の光学活性体の製造法
JP2867462B2 (ja) 1989-09-12 1999-03-08 藤沢薬品工業株式会社 経皮吸収用製剤
JP2920956B2 (ja) 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US5258393A (en) * 1990-02-21 1993-11-02 Fujisawa Pharmaceutical Co., Ltd. Use of a dihydropyridine compound for improving inner ear microcirculation
WO1992003137A1 (en) 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1993005770A1 (fr) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation a longue duree d'action
JPH05139974A (ja) 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
DE4141646A1 (de) 1991-12-17 1993-06-24 Klinge Co Chem Pharm Fab Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4229805A1 (de) 1992-09-07 1994-03-24 Werner E G Prof Dr Mueller Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
ATE204163T1 (de) * 1993-06-30 2001-09-15 Fujisawa Pharmaceutical Co Verkapselter arzneistoff
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP3541389B2 (ja) * 1996-04-26 2004-07-07 藤沢薬品工業株式会社 ジヒドロピリジン化合物を含有する眼組織末梢循環改善剤
US6271259B1 (en) * 1996-05-07 2001-08-07 Ito En, Ltd. Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death
KR100222306B1 (ko) 1996-11-20 1999-10-01 이병언 닐바디핀 속효성 고형제제 및 이의 제조방법
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
EP1085863A4 (en) 1998-06-08 2001-03-28 Advanced Medicine Inc NEW MEDICINES FOR THE TREATMENT OF FAULTS CAUSED BY CALCIUM CHANNELS AND THEIR USE
WO1999064045A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
SI1096932T1 (sl) 1998-07-10 2008-04-30 Novartis Pharma Ag Antihipertenzivna kombinacija valsartana in zaviralca kalcijevih kanalov
EP1260232A1 (en) 2000-03-03 2002-11-27 Fujisawa Pharmaceutical Co., Ltd. Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof
BR0109991A (pt) 2000-04-11 2003-05-27 Sankyo Co Composição farmacêutica
JP2001335483A (ja) 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
CA2415826A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP3968687B2 (ja) 2000-09-13 2007-08-29 東和薬品株式会社 易吸収性ニルバジピン錠
JP3470096B2 (ja) 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
CA2431074A1 (en) * 2000-12-19 2002-06-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1)
CN1481244A (zh) * 2000-12-19 2004-03-10 Ĭ��ר���ɷ����޹�˾ 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
EP1392287B8 (en) 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
TW200306799A (en) 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
ES2369216T3 (es) 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
JP2003146878A (ja) 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
EA012325B1 (ru) 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
CN100444840C (zh) * 2003-05-15 2008-12-24 罗斯坎普研究有限公司 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物
JP2004002460A (ja) 2003-07-29 2004-01-08 Towa Yakuhin Kk 易吸収性ニルバジピン錠の製造法
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer

Also Published As

Publication number Publication date
RU2010117634A (ru) 2011-11-10
MX2010003669A (es) 2010-11-25
US8236346B2 (en) 2012-08-07
DK2214666T3 (da) 2014-01-27
US20090092667A1 (en) 2009-04-09
KR20100067683A (ko) 2010-06-21
US8236347B2 (en) 2012-08-07
JP2010540661A (ja) 2010-12-24
TW200920364A (en) 2009-05-16
EP2214666A4 (en) 2010-12-08
AU2008308519A1 (en) 2009-04-09
TWI500422B (zh) 2015-09-21
EP2214666A1 (en) 2010-08-11
NZ584729A (en) 2012-12-21
AU2008308519A2 (en) 2010-04-29
US20100183711A1 (en) 2010-07-22
CN101883564B (zh) 2013-10-16
PL2214666T3 (pl) 2014-06-30
WO2009046323A1 (en) 2009-04-09
KR101417200B1 (ko) 2014-08-01
CN101883564A (zh) 2010-11-10
CA2701620A1 (en) 2009-04-09
CA2701620C (en) 2014-12-09
AU2008308519B2 (en) 2014-09-11
JP5411145B2 (ja) 2014-02-12
EP2214666B1 (en) 2013-12-11
RU2490014C2 (ru) 2013-08-20
ES2449594T3 (es) 2014-03-20

Similar Documents

Publication Publication Date Title
BRPI0807755A2 (pt) Sementes revestidas e métodos para fabricação de sementes revestidas.
BRPI0812054A2 (pt) Processo para preparar compostos, e, compostos.
BRPI0817402A2 (pt) dispositivos e métodos para automação de fluxos de trabalho, adaptação e integração
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI0912221A2 (pt) método para produzir nanofibras inorgânicas.
BRPI0814466A2 (pt) Método.
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BRPI0921310A2 (pt) método para fabricar um compósito, compósito, e, aparelho
BRPI0906706A2 (pt) Conjuntos de válvulas
BRPI1010658A2 (pt) métodos para integrar múltiplos domínios de gerenciamento
BRPI0806943A2 (pt) Utensílio de dispensação e método de fabricação para o mesmo
BRPI0821729A2 (pt) Tapete, revestimento de tapete e método para fabricar um tapete
BRPI0819127A2 (pt) Método para cimentar.
MX325514B (es) Metodo para elaborar cetales y acetales.
BRPI0911531A2 (pt) processo para preparar iopromida, e, composto.
BRPI0720174A2 (pt) Processo para modificação da resistência de plantas a insetos através da utilização da técnica de rnai
BRPI1014547A2 (pt) composto, e, processo para preparar um composto.
BR112014005411A2 (pt) invólucro de cilindro, e método para fabricar o mesmo
BRPI0911898A2 (pt) processo para preparar compostos, e, composto.
BRPI0909204A2 (pt) Estator, e aparelho para a fabricação do estator
BRPI0815796A2 (pt) Compósito elastomérico e método para produzi-lo.
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
BRPI0823031A2 (pt) Conjunto, e , método para fabricar um conjunto
BRPI0807973A2 (pt) Método de enrolamento de propriedades uniformes
BRPI0914924A2 (pt) processo para preparar aminobifenilas, e, composto.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL